47.71 USD
-1.67 (-3.38%)
47.62 USD
-0.09 (-0.19%)
Overall VCYT gets a fundamental rating of 6 out of 10. We evaluated VCYT against 533 industry peers in the Biotechnology industry. VCYT has an excellent financial health rating, but there are some minor concerns on its profitability. VCYT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year VCYT was profitable.
In the past year VCYT had a positive cash flow from operations.
VCYT had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: VCYT reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of VCYT (2.22%) is better than 89.87% of its industry peers.
Looking at the Return On Equity, with a value of 2.41%, VCYT belongs to the top of the industry, outperforming 90.99% of the companies in the same industry.
VCYT's Return On Invested Capital of 2.93% is amongst the best of the industry. VCYT outperforms 90.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROIC | 2.93% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VCYT has a Profit Margin of 6.12%. This is amongst the best in the industry. VCYT outperforms 90.81% of its industry peers.
VCYT's Operating Margin of 9.70% is amongst the best of the industry. VCYT outperforms 91.74% of its industry peers.
Looking at the Gross Margin, with a value of 68.53%, VCYT belongs to the top of the industry, outperforming 80.68% of the companies in the same industry.
In the last couple of years the Gross Margin of VCYT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so VCYT is destroying value.
VCYT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for VCYT has been increased compared to 5 years ago.
VCYT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
VCYT has an Altman-Z score of 21.55. This indicates that VCYT is financially healthy and has little risk of bankruptcy at the moment.
VCYT has a better Altman-Z score (21.55) than 90.24% of its industry peers.
VCYT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 21.55 |
ROIC/WACC0.34
WACC8.65%
2.3 Liquidity
VCYT has a Current Ratio of 6.23. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
VCYT has a Current ratio of 6.23. This is in the better half of the industry: VCYT outperforms 65.67% of its industry peers.
VCYT has a Quick Ratio of 5.94. This indicates that VCYT is financially healthy and has no problem in meeting its short term obligations.
VCYT has a better Quick ratio (5.94) than 63.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 353.33% over the past year.
VCYT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 16.41%.
Measured over the past years, VCYT shows a very strong growth in Revenue. The Revenue has been growing by 29.93% on average per year.
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
3.2 Future
The Earnings Per Share is expected to grow by 50.66% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 9.91% on average over the next years. This is quite good.
EPS Next Y33.17%
EPS Next 2Y67.82%
EPS Next 3Y57.77%
EPS Next 5Y50.66%
Revenue Next Year12.89%
Revenue Next 2Y11.38%
Revenue Next 3Y10.9%
Revenue Next 5Y9.91%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VCYT is valuated quite expensively with a Price/Earnings ratio of 125.55.
Compared to the rest of the industry, the Price/Earnings ratio of VCYT indicates a rather cheap valuation: VCYT is cheaper than 89.12% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.15. VCYT is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 56.47, VCYT can be considered very expensive at the moment.
VCYT's Price/Forward Earnings ratio is rather cheap when compared to the industry. VCYT is cheaper than 89.31% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.12. VCYT is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 125.55 | ||
| Fwd PE | 56.47 |
4.2 Price Multiples
VCYT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. VCYT is cheaper than 90.62% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, VCYT is valued cheaper than 92.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.22 | ||
| EV/EBITDA | 49.26 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
VCYT has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as VCYT's earnings are expected to grow with 57.77% in the coming years.
PEG (NY)3.79
PEG (5Y)N/A
EPS Next 2Y67.82%
EPS Next 3Y57.77%
5. Dividend
5.1 Amount
No dividends for VCYT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
47.71
-1.67 (-3.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners109.55%
Inst Owner Change3.31%
Ins Owners0.56%
Ins Owner Change-1.68%
Market Cap3.75B
Revenue(TTM)495.14M
Net Income(TTM)30.32M
Analysts83.33
Price Target48.22 (1.07%)
Short Float %7.72%
Short Ratio6.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-110.32%
Max EPS beat(2)79.03%
EPS beat(4)2
Avg EPS beat(4)-1.91%
Min EPS beat(4)-110.32%
Max EPS beat(4)79.03%
EPS beat(8)5
Avg EPS beat(8)108.97%
EPS beat(12)8
Avg EPS beat(12)67.3%
EPS beat(16)12
Avg EPS beat(16)58.01%
Revenue beat(2)2
Avg Revenue beat(2)4.54%
Min Revenue beat(2)3.31%
Max Revenue beat(2)5.76%
Revenue beat(4)3
Avg Revenue beat(4)2.42%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)5.76%
Revenue beat(8)7
Avg Revenue beat(8)4.03%
Revenue beat(12)11
Avg Revenue beat(12)4.6%
Revenue beat(16)15
Avg Revenue beat(16)5.32%
PT rev (1m)14.68%
PT rev (3m)14.68%
EPS NQ rev (1m)10.34%
EPS NQ rev (3m)16.36%
EPS NY rev (1m)5.86%
EPS NY rev (3m)6.58%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)0.46%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.29%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 125.55 | ||
| Fwd PE | 56.47 | ||
| P/S | 7.58 | ||
| P/FCF | 38.22 | ||
| P/OCF | 34.67 | ||
| P/B | 2.98 | ||
| P/tB | 9.43 | ||
| EV/EBITDA | 49.26 |
EPS(TTM)0.38
EY0.8%
EPS(NY)0.84
Fwd EY1.77%
FCF(TTM)1.25
FCFY2.62%
OCF(TTM)1.38
OCFY2.88%
SpS6.29
BVpS15.99
TBVpS5.06
PEG (NY)3.79
PEG (5Y)N/A
Graham Number11.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.22% | ||
| ROE | 2.41% | ||
| ROCE | 3.71% | ||
| ROIC | 2.93% | ||
| ROICexc | 4.08% | ||
| ROICexgc | 54.52% | ||
| OM | 9.7% | ||
| PM (TTM) | 6.12% | ||
| GM | 68.53% | ||
| FCFM | 19.83% |
ROA(3y)-2.66%
ROA(5y)-4.4%
ROE(3y)-2.83%
ROE(5y)-4.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.39%
GM growth 5Y-0.79%
F-Score8
Asset Turnover0.36
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 44.87% | ||
| Cap/Sales | 2.03% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.79% | ||
| Profit Quality | 323.94% | ||
| Current Ratio | 6.23 | ||
| Quick Ratio | 5.94 | ||
| Altman-Z | 21.55 |
F-Score8
WACC8.65%
ROIC/WACC0.34
Cap/Depr(3y)39.24%
Cap/Depr(5y)36.19%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)353.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.32%
EPS Next Y33.17%
EPS Next 2Y67.82%
EPS Next 3Y57.77%
EPS Next 5Y50.66%
Revenue 1Y (TTM)16.41%
Revenue growth 3Y26.64%
Revenue growth 5Y29.93%
Sales Q2Q%13.82%
Revenue Next Year12.89%
Revenue Next 2Y11.38%
Revenue Next 3Y10.9%
Revenue Next 5Y9.91%
EBIT growth 1Y426.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year275.46%
EBIT Next 3Y68.01%
EBIT Next 5Y45.61%
FCF growth 1Y237.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y181.75%
OCF growth 3YN/A
OCF growth 5YN/A
VERACYTE INC / VCYT FAQ
What is the fundamental rating for VCYT stock?
ChartMill assigns a fundamental rating of 6 / 10 to VCYT.
What is the valuation status for VCYT stock?
ChartMill assigns a valuation rating of 5 / 10 to VERACYTE INC (VCYT). This can be considered as Fairly Valued.
How profitable is VERACYTE INC (VCYT) stock?
VERACYTE INC (VCYT) has a profitability rating of 6 / 10.
How financially healthy is VERACYTE INC?
The financial health rating of VERACYTE INC (VCYT) is 8 / 10.
What is the expected EPS growth for VERACYTE INC (VCYT) stock?
The Earnings per Share (EPS) of VERACYTE INC (VCYT) is expected to grow by 33.17% in the next year.